Merck strengthens growth narrative, Bristol-Myers Squibb difficult to own - BMO Capital…
BMY earnings call for the period ending September 30, 2023.…
These are the stocks posting the largest moves in midday trading.…
…
By Brad Sorensen, CFA
NASDAQ:SCLX
READ THE FULL SCLX RESEARCH REPORT
Scilex Holding Company (NASDAQ:SCLX) is a revenue-generating company that is focused on…
Shares of Bristol-Myers Squibb Co (NYSE:BMY) dropped 4% in pre-market trading, erasing nearly $5 billion from the pharmaceutical companys market value....…
…
Bristol-Myers Squibb falls despite raised full-year profit guidance…
Bristol-Myers Squibb Co. BMY on Thursday posted net income of $1.928 billion, or 93 cents a share, for the third…
Bristol Myers Squibb’s revenue was in line with estimates, but fell slightly from the same period last year due to…
Investors are loving LianBios new deal with Bristol Myers Squibb.…
…
MONSEY, N.Y., Oct. 20, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating…
Bristol Myers Squibb recently announced an acquisition that should strengthen its oncology portfolio.…
Bristol Myers Squibb recently announced an acquisition that should strengthen its oncology portfolio.…
Institutional Investors Dominate Bristol-Myers Squibb’s Shareholding Structure…
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.Im Rahmen dieser erweiterten Vereinbarung stellt Cellares…
Questo report è stato trasmesso da Businesswire. Solo lazienda emittente è resposabile del suo contenuto.In base a tale accordo ampliato,…
Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer are part of the Zacks top Analyst Blog.…
Die Mirati-Aktionäre sollen 58 Dollar pro Aktie in bar erhalten, teilte der Pharmakonzern am Sonntag in New York mit. Zudem…
Bristol-Myers Squibb shells out $5.8B for Mirati: 5 big deal reports…
Bristol-Myers Squibb to acquire Mirati in a deal worth up to $5.8 billion…
Shares in RTX, Lockheed Martin, Marathon Oil, Occidental Petroleum, Mirati Therapeutics, and Bristol Myers Squibb Co. were on the move…
Die Mirati-Aktionäre sollen 58 Dollar pro Aktie in bar erhalten, teilte der Pharmakonzern am Sonntag in New York mit. Zudem…
Die Mirati-Aktionäre sollen 58 Dollar pro Aktie in bar erhalten, teilte der Pharmakonzern am Sonntag in New York mit. Zudem…
NEW YORK (dpa-AFX) - Der US-Pharmakonzern Bristol Myers Squibb (BMS) will mit der Übernahme des Krebsmedikamentenherstellers Mirati Therapeutics für…
Frankfurt (Reuters) - Der US-Pharmakonzern Bristol-Myers Squibb schluckt den Krebsspezialisten Mirati Therapeutics in einem bis zu 5,8 Milliarden Dollar schweren…
Kulmbach (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Bristol-Myers…
Bereits in der vorangegangenen Handelswoche haben sich frische Übernahmegerüchte rund um den Präzisionsonkologie-Spezialisten Mirati Therapeutics gehalten. Konkret wurde Sanofi entsprechendes…
Bereits in der vorangegangenen Handelswoche haben sich frische Übernahmegerüchte rund um den Präzisionsonkologie-Spezialisten Mirati Therapeutics gehalten. Konkret wurde Sanofi entsprechendes…
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion…
Mirati develops commercial-stage oncology therapies, and through the deal, Bristol Myers Squibb will add lung-cancer medicine Krazati, among others,…
Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal…
Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing $4.8 billion equity…
Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing $4.8 billion equity…
…
London (www.aktiencheck.de) - Rating-Update:
Carter Gould, Analyst von Barclays, stuft die Bristol-Myers Squibb-Aktie (ISIN: US1101221083, WKN: 850501, Ticker-Symbol: BRM, NYSE Ticker-Symbol:…
The dynamics of the eosinophilic esophagitis market are anticipated to change in the coming years owing to the expected launch…
[230 + Pages Report] According to a market research study published by The Brainy Insights, the demand analysis of Global…
[230+ Pages Report] According to a market research study published by The Brainy Insights, the demand analysis of Global…
Leading IBD (Ulcerative Colitis and Crohns Disease) Treatment Market players include Bausch Health Companies Inc., AbbVie Inc., Novartis AG, Bristol…
Der amerikanische Pharmakonzern Bristol-Myers Squibb Co. (ISIN: US1101221083, NYSE: BMY) wird seinen Aktionären am 1. November 2023 eine vierteljährliche Dividende…
…
…
read more...…
Bristol Myers (BMY) repotrectinib shows durable efficacy benefits in patients with locally advanced or metastatic ROS1-Positive non-small cell lung cancer....…
How a researchers 12-year journey to a new Bristol-Myers psoriasis medicine became personal: “You have hopes and daydreams almost in…
NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Co. (BMY), a pharma major, said on Thursday that it has inked agreements…
Bristol Myers Sets $4 Billion Accelerated Stock Buyback >BMY...…
Shares of Bristol Myers Squibb Co. BMY got a 0.9% bump up in premarket trading Thursday, after the biopharmaceutical company…